Guoxiong Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Guoxiong Deng has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Liang Ma
Department of Clinical Laboratory, China-Japan Friendship Hospital
2 shared publications - Meimei Zhao
Department of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China
2 shared publications - Peng Gao
Department of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China
2 shared publications - Xiaomu Kong
Department of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China
2 shared publications - Yi Liu
Department of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China
2 shared publications - Yongwei Jiang
Department of Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Diabetes Research
- Vol. 2026 (1) , e9298888
Clinical Validation of Digital PCR for Precise m.3243A>G Heteroplasmy Quantification in Early‐Onset Diabetes
Background: Mitochondrial DNA m.3243A>G variant causes maternally inherited diabetes with deafness. We developed a droplet digital PCR (dPCR) assay to quantify m.3243A>G heteroplasmy and investigated its prevalence in Chinese Han early‐onset diabetes patients. Methods: The dPCR method was validated using plasmid mixtures (10 4 copies) for sensitivity, specificity, dynamic range (10–10 5 copies/μL), accuracy, and precision. We screened 1506 unselected early‐onset diabetes patients, analyzing blood and urinary sediment DNA. This population comprised 1474 diagnosed type 2 diabetes patients (97.88%), 31 diagnosed type 1 diabetes patients (2.06%), and one patient with mitochondrial diabetes (0.07%). The dPCR results were compared with Sanger sequencing and next generation sequencing (NGS) to evaluate the accuracy of heteroplasmy rate quantification. Results: The dynamic range spans from 10 to 10 5 copies/μL. The assay detected heteroplasmy as low as 0.05% with 100% specificity. The method can reliably quantify the heteroplasmy rate at 0% to 100% for an input copy number of 10 4 . Using the dPCR method, we identified 0.80% ( n = 12) had >5% m.3243A>G heteroplasmy in peripheral blood and/or urinary sediment, and 0.40% ( n = 6) had 1%–5% among the early‐onset diabetes patients. The dPCR approach was more sensitive than Sanger sequencing. When compared with NGS results, the dPCR method accurately genotyped m.3243A>G and quantified its heteroplasmy rate in clinical samples. Furthermore, it demonstrated that urine is a reliable noninvasive sample source for determining the m.3243A>G heteroplasmy rate. Conclusion: The developed method can provide an accurate, reliable, rapid, simple, and low‐cost evaluation of the heteroplasmy rate of m.3243A>G for both peripheral blood and urinary sediment. Thus, it is highly promising as a genetic screening method for early‐onset diabetes related to m.3243A>G.
- 1 January 2026
- Published by Wiley in Journal of Diabetes Research
- Vol. 2026 (1) , e9298888
Open AccessClinical Validation of Digital PCR for Precise m.3243A>G Heteroplasmy Quantification in Early‐Onset Diabetes
Background: Mitochondrial DNA m.3243A>G variant causes maternally inherited diabetes with deafness. We developed a droplet digital PCR (dPCR) assay to quantify m.3243A>G heteroplasmy and investigated its prevalence in Chinese Han early‐onset diabetes patients. Methods: The dPCR method was validated using plasmid mixtures (10 4 copies) for sensitivity, specificity, dynamic range (10–10 5 copies/μL), accuracy, and precision. We screened 1506 unselected early‐onset diabetes patients, analyzing blood and urinary sediment DNA. This population comprised 1474 diagnosed type 2 diabetes patients (97.88%), 31 diagnosed type 1 diabetes patients (2.06%), and one patient with mitochondrial diabetes (0.07%). The dPCR results were compared with Sanger sequencing and next generation sequencing (NGS) to evaluate the accuracy of heteroplasmy rate quantification. Results: The dynamic range spans from 10 to 10 5 copies/μL. The assay detected heteroplasmy as low as 0.05% with 100% specificity. The method can reliably quantify the heteroplasmy rate at 0% to 100% for an input copy number of 10 4 . Using the dPCR method, we identified 0.80% ( n = 12) had >5% m.3243A>G heteroplasmy in peripheral blood and/or urinary sediment, and 0.40% ( n = 6) had 1%–5% among the early‐onset diabetes patients. The dPCR approach was more sensitive than Sanger sequencing. When compared with NGS results, the dPCR method accurately genotyped m.3243A>G and quantified its heteroplasmy rate in clinical samples. Furthermore, it demonstrated that urine is a reliable noninvasive sample source for determining the m.3243A>G heteroplasmy rate. Conclusion: The developed method can provide an accurate, reliable, rapid, simple, and low‐cost evaluation of the heteroplasmy rate of m.3243A>G for both peripheral blood and urinary sediment. Thus, it is highly promising as a genetic screening method for early‐onset diabetes related to m.3243A>G.
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1) , 8096423
Association Between DNA Methylation of MTHFR and Diabetic Kidney Disease
Objective: The objective of this study is to explore the association between MTHFR DNA methylation and diabetic kidney disease (DKD). Methods: This study involved 120 healthy people, 200 diabetes mellitus (DM) patients, and 200 DKD patients who visited China–Japan Friendship Hospital from 2022 to 2023. We selected four CpG islands for the detection of MTHFR DNA methylation: three located in the promoter region and one in Exon 2. The methylation rate of the MTHFR gene was measured using an enzyme digestion method combined with quantitative PCR. Clinical and biochemical characteristics between the two groups were also collected. Results: The methylation rate of the three CpG islands in the promoter region showed no significant differences between the DM and DKD patients. However, a significant difference in the CpG island methylation rate of the MTHFR gene Exon 2 was observed (25.14% vs. 21.94%, p < 0.001). Logistic regression analysis indicated that the methylation rate of MTHFR Exon2 is negatively associated with the occurrence and progression of DKD (OR = 0.947, 95% CI [0.919, 0.977], p = 0.001), with adjustments for gender, age, BMI, smoking, drinking, CHO, and TG. Significant differences were observed in the methylation ratios in different HCY groups (24.51% vs. 21.99%, p = 0.031). Linear regression showed MTHFR Exon 2 methylation negatively correlated with homocysteine (HCY) levels ( p = 0.007). Conclusion: Methylation of the MTHFR gene Exon 2 is a protective factor for DKD and may contribute to its onset and progression through its influence on HCY levels. These findings highlight the potential of MTHFR methylation as a biomarker for DKD.
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1) , 8096423
Open AccessAssociation Between DNA Methylation of MTHFR and Diabetic Kidney Disease
Objective: The objective of this study is to explore the association between MTHFR DNA methylation and diabetic kidney disease (DKD). Methods: This study involved 120 healthy people, 200 diabetes mellitus (DM) patients, and 200 DKD patients who visited China–Japan Friendship Hospital from 2022 to 2023. We selected four CpG islands for the detection of MTHFR DNA methylation: three located in the promoter region and one in Exon 2. The methylation rate of the MTHFR gene was measured using an enzyme digestion method combined with quantitative PCR. Clinical and biochemical characteristics between the two groups were also collected. Results: The methylation rate of the three CpG islands in the promoter region showed no significant differences between the DM and DKD patients. However, a significant difference in the CpG island methylation rate of the MTHFR gene Exon 2 was observed (25.14% vs. 21.94%, p < 0.001). Logistic regression analysis indicated that the methylation rate of MTHFR Exon2 is negatively associated with the occurrence and progression of DKD (OR = 0.947, 95% CI [0.919, 0.977], p = 0.001), with adjustments for gender, age, BMI, smoking, drinking, CHO, and TG. Significant differences were observed in the methylation ratios in different HCY groups (24.51% vs. 21.99%, p = 0.031). Linear regression showed MTHFR Exon 2 methylation negatively correlated with homocysteine (HCY) levels ( p = 0.007). Conclusion: Methylation of the MTHFR gene Exon 2 is a protective factor for DKD and may contribute to its onset and progression through its influence on HCY levels. These findings highlight the potential of MTHFR methylation as a biomarker for DKD.
- 1 July 2018
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (13_Supplem) , 4292
Abstract 4292: Negative regulation of oncogenes by a novel tumor suppressor microRNA in prostate cancer
Background: MicroRNAs are small noncoding RNAs that regulate the expression of >60% of all human genes, either inhibiting target mRNA translation or inducing its degradation. MicroRNAs act as tumor suppressors or oncogenes in various cancers. The main objective of this study was to investigate the role of microRNA-588 (miR-588) in prostate cancer (PC). Methods: The methods employed in this study include quantitative-real time PCR; western blot; fluorescence-activated cell sorting assays for cell cycle distribution and apoptosis; assays for cell viability, migration and invasiveness of prostate cancer cells. Luciferase reporter assays and in-vivo study in nude mice was also performed. Results: The expression of miR-588 was significantly suppressed or silenced in PC tissue samples and cell lines when compared with normal tissues and a non-malignant cell line. Similar results were observed by analyzing the publicly available TCGA data sets for prostate adenocarcinoma. Functionally ectopic expression of miR-588 induced G0/G1 cell cycle arrest and apoptosis and suppressed cell proliferation. miR-588 exerted these functional effects by directly targeting the oncogenic Cyclin A2 that is involved in cancer cell cycle and proliferation. In silico algorithm showed a complimentary binding sequence in the 3'UTR of Cyclin A2 for miR-588. Over-expression of miR-588 significantly suppressed the luciferase activity of reporter plasmid containing the wild type 3'UTR sequences of cyclin A2 complementary to miR-588, which was abolished by mutations in these 3'UTR regions. miR-588 overexpression also significantly reduced the expression of cyclin A2 at both mRNA and protein levels. A significant decrease in the expression of various cell cycle pathway genes such as CycE1, MCM2, MCM4, CDC7 and CDT1 was also observed. These genes are involved in promoting cell cycle and proliferation and are overexpressed in prostate cancer. In vivo intracardiac implantation of PC3-MLuc-C6 prostate cancer cells constitutively expressing miR-588 showed a significant inhibition of the metastatic dissemination of these cells compared to the control miR expressing cells. Conclusion: This is the first study demonstrating that miR-588 is significantly silenced and acts as a tumor suppressor in prostate cancer. Reconstitution of silenced miR-588 may contribute to novel therapeutic approaches for regulating prostate cancer. Citation Format: Nadeem Bhat, Altaf A. Dar, Sharanjot Saini, Varahram Shahryari, Priyanka Kulkarni, Pritha Dasgupta, Soichiro Yamamura, Yuichiro Tanaka, Taku Kato, Yutaka Hashimoto, Marisa Shiina, Z. Laura Tabatabai, Guoren Deng, Rajvir Dahiya, Shahana Majid. Negative regulation of oncogenes by a novel tumor suppressor microRNA in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4292.
- 1 July 2018
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 78 (13_Supplem) , 4292
Abstract 4292: Negative regulation of oncogenes by a novel tumor suppressor microRNA in prostate cancer
Background: MicroRNAs are small noncoding RNAs that regulate the expression of >60% of all human genes, either inhibiting target mRNA translation or inducing its degradation. MicroRNAs act as tumor suppressors or oncogenes in various cancers. The main objective of this study was to investigate the role of microRNA-588 (miR-588) in prostate cancer (PC). Methods: The methods employed in this study include quantitative-real time PCR; western blot; fluorescence-activated cell sorting assays for cell cycle distribution and apoptosis; assays for cell viability, migration and invasiveness of prostate cancer cells. Luciferase reporter assays and in-vivo study in nude mice was also performed. Results: The expression of miR-588 was significantly suppressed or silenced in PC tissue samples and cell lines when compared with normal tissues and a non-malignant cell line. Similar results were observed by analyzing the publicly available TCGA data sets for prostate adenocarcinoma. Functionally ectopic expression of miR-588 induced G0/G1 cell cycle arrest and apoptosis and suppressed cell proliferation. miR-588 exerted these functional effects by directly targeting the oncogenic Cyclin A2 that is involved in cancer cell cycle and proliferation. In silico algorithm showed a complimentary binding sequence in the 3'UTR of Cyclin A2 for miR-588. Over-expression of miR-588 significantly suppressed the luciferase activity of reporter plasmid containing the wild type 3'UTR sequences of cyclin A2 complementary to miR-588, which was abolished by mutations in these 3'UTR regions. miR-588 overexpression also significantly reduced the expression of cyclin A2 at both mRNA and protein levels. A significant decrease in the expression of various cell cycle pathway genes such as CycE1, MCM2, MCM4, CDC7 and CDT1 was also observed. These genes are involved in promoting cell cycle and proliferation and are overexpressed in prostate cancer. In vivo intracardiac implantation of PC3-MLuc-C6 prostate cancer cells constitutively expressing miR-588 showed a significant inhibition of the metastatic dissemination of these cells compared to the control miR expressing cells. Conclusion: This is the first study demonstrating that miR-588 is significantly silenced and acts as a tumor suppressor in prostate cancer. Reconstitution of silenced miR-588 may contribute to novel therapeutic approaches for regulating prostate cancer. Citation Format: Nadeem Bhat, Altaf A. Dar, Sharanjot Saini, Varahram Shahryari, Priyanka Kulkarni, Pritha Dasgupta, Soichiro Yamamura, Yuichiro Tanaka, Taku Kato, Yutaka Hashimoto, Marisa Shiina, Z. Laura Tabatabai, Guoren Deng, Rajvir Dahiya, Shahana Majid. Negative regulation of oncogenes by a novel tumor suppressor microRNA in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 4292.
- 1 March 1994
- Published by Wiley in Seminars in Surgical Oncology
- Vol. 10 (2) , 83-87
Activation of oncogene c‐Ha‐ras in gastric cancer of chinese patients
A transforming gene was cloned from a focus of rat fibroblast cell line Rat 1 transfected with DNA of a gastrocarcinoma cell line. The transforming gene is the activated form of oncogene c‐Ha‐ras, and the lesion was identified as a single nucleotide substitution at codon 12 by sequencing. We further used polymerase chain reaction (PCR)‐restriction analysis to detect the mutations at codon 12 of c‐Ha‐ras. By using this method, 11 cases out of 24 solid tumors and 3 cell lines of gastric cancer were shown to contain mutations, and there was a strong correlation between mutations and metastasis and survival of the patients. The role of the activated c‐Ha‐ras in tumorigenesis of stomach cancer was further proved through the assay in which the malignant phenotypes of the c‐Ha‐ras‐transformed cells were partially inhibited by blocking the c‐Ha‐ras expression with antisense oligonucleotides or exogenous plasmid expressing antisense RNA.
- 1 March 1994
- Published by Wiley in Seminars in Surgical Oncology
- Vol. 10 (2) , 83-87
Activation of oncogene c‐Ha‐ras in gastric cancer of chinese patients
A transforming gene was cloned from a focus of rat fibroblast cell line Rat 1 transfected with DNA of a gastrocarcinoma cell line. The transforming gene is the activated form of oncogene c‐Ha‐ras, and the lesion was identified as a single nucleotide substitution at codon 12 by sequencing. We further used polymerase chain reaction (PCR)‐restriction analysis to detect the mutations at codon 12 of c‐Ha‐ras. By using this method, 11 cases out of 24 solid tumors and 3 cell lines of gastric cancer were shown to contain mutations, and there was a strong correlation between mutations and metastasis and survival of the patients. The role of the activated c‐Ha‐ras in tumorigenesis of stomach cancer was further proved through the assay in which the malignant phenotypes of the c‐Ha‐ras‐transformed cells were partially inhibited by blocking the c‐Ha‐ras expression with antisense oligonucleotides or exogenous plasmid expressing antisense RNA.